Antonio Camera
YOU?
Author Swipe
View article: Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients Open
BACKGROUNDTebentafusp is the first T cell receptor-based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T cells toward gp100-expressing target cells, fr…
View article: Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells Open
Sarcomas are rare, mesenchymal tumors, representing about 10-15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several solid tumors. In this preclinical s…
View article: Supplemental Figure 13 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 13 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 13. Evaluation of GD2 expression on DAOY cells pre and post treatment with Tazemetostat.
View article: Supplemental Figure 17 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 17 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 17. Evaluation of the NT T-cell infiltration in MB xenograft mouse model.
View article: Supplemental Figure 10 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 10 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 10. In vivo experiment of NSG mice bearing D283 Med-GFP-FF-Luc cells treated with NT or CAR.GD2 T-cells.
View article: Supplemental Figure 14 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 14 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 14. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity of CAR.GD2 T-cells.
View article: Supplemental Figure 16 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 16 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 16. Evaluation of the efficacy of AP1903 CAR.GD2 T-cells infiltrating tumor in in vivo MB xenograft mouse model.
View article: Supplemental Figure 6 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 6 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 6. CAR.GD2 T-cells spare the elimination of MB cells with a dim expression of GD2.
View article: Supplemental Figure 13 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 13 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 13. Evaluation of GD2 expression on DAOY cells pre and post treatment with Tazemetostat.
View article: Supplemental Figure 4 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 4 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 4. Real-Time killing assay of CAR.GD2 T-cells vs D283 Med-GFP-FF-Luc cell line.
View article: Supplemental Figure 8 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 8 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 8. Tazemetostat did not modulate GD2 expression in normal cells.
View article: Supplemental Figure 11 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 11 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 11. Quantification of murine plasma neurofilament (NFL) levels in an orthotopic mouse model of the human DAOY-GFP cell line, treated with NT or CAR.GD2 T-cells.
View article: Supplemental Figure 17 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 17 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 17. Evaluation of the NT T-cell infiltration in MB xenograft mouse model.
View article: Data from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Data from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Purpose:Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cogni…
View article: Supplemental Figure 1 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 1 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 1. Representative dot plots of GD2 expression in MB patients.
View article: Data from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Data from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Purpose:Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cogni…
View article: Supplemental Figure 8 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 8 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 8. Tazemetostat did not modulate GD2 expression in normal cells.
View article: Supplemental Figure 10 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 10 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 10. In vivo experiment of NSG mice bearing D283 Med-GFP-FF-Luc cells treated with NT or CAR.GD2 T-cells.
View article: Supplemental Video 1 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Video 1 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Video 1. IncuCyte® live-cell System video of cytotoxic activity of NT or CAR.GD2 T-cells vs D283 Med-GFP-FF-Luc cell line. The video shows 84 hours of tumor growth (D283 Med cell line) with only tumor cells (A) and those of tu…
View article: Supplemental Figure 15 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 15 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 15. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity of CAR.GD2 T-cells and the in vivo modulation of GD2 expression.
View article: Supplemental Figure 7 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 7 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 7. Inhibition of EZH2 with Tazemetostat upregulates GD2 expression in MED-411 FHTC (G3 subgroup) MB cells.
View article: Supplemental Figure 3 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 3 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 3. CAR-GD2.CD28.4-1BBζ T-cells exhibit high and stable transduction level.
View article: Supplemental Figure 16 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 16 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 16. Evaluation of the efficacy of AP1903 CAR.GD2 T-cells infiltrating tumor in in vivo MB xenograft mouse model.
View article: Supplemental Figure 14 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 14 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 14. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity of CAR.GD2 T-cells.
View article: Supplemental Figure 4 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 4 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 4. Real-Time killing assay of CAR.GD2 T-cells vs D283 Med-GFP-FF-Luc cell line.
View article: Supplemental Figure 5 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 5 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 5. Real-Time killing assay of CAR.GD2 T-cells vs DAOY-GFP cell line.
View article: Supplemental Figure 11 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 11 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 11. Quantification of murine plasma neurofilament (NFL) levels in an orthotopic mouse model of the human DAOY-GFP cell line, treated with NT or CAR.GD2 T-cells.
View article: Supplemental Figure 2 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 2 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 2. GD2 evaluation in MB cell lines.
View article: Supplemental Figure 7 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 7 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 7. Inhibition of EZH2 with Tazemetostat upregulates GD2 expression in MED-411 FHTC (G3 subgroup) MB cells.
View article: Supplemental Figure 3 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma
Supplemental Figure 3 from GD2-Targeting CAR T-cell Therapy for Patients with GD2<sup>+</sup> Medulloblastoma Open
Supplemental Figure 3. CAR-GD2.CD28.4-1BBζ T-cells exhibit high and stable transduction level.